Latest News

Looking for older news? View News Archive >


Ampio updates status of clinical trials and manufacturing facility

Date: November 12, 2014 | READ MORE >

Luoxis to Highlight RedoxSYS at Two Upcoming Scientific Conferences

Date: October 20, 2014 | READ MORE >

Ampio Announces Results of the Open Label Portion of the Multiple Intra-articular Injections (MI) Study of Ampion™ in Patients with Osteoarthritis of the Knee at Week Twelve of the Trial

Date: October 17, 2014 | READ MORE >

Ampio Pharmaceuticals Announces Webcast for Annual Shareholder Meeting

Date: September 15, 2014 | READ MORE >

Update on the Phase III multicenter, double-blind STEP study of Ampion™ for Osteoarthritis of the Knee

Date: September 2, 2014 | READ MORE >

Letter to the Ampio Shareholders in Regard to the STEP Study and Ampio’s plans for the Ampion™ BLA

Date: August 27, 2014 | READ MORE >

Ampio reports that due to temperature deviations below product specifications during shipments to the Ampion™ STEP Study clinical sites, release of data will be delayed.

Date: August 21, 2014 | READ MORE >

Analysis of Available Data from OptimEyes study (Blinded and Open Label) of Optina™ for the Treatment of Diabetic Macular Edema (DME) indicates Potential for Significant Clinical Benefit

Date: August 20, 2014 | READ MORE >

Luoxis Announces Presentation of Positive Clinical Findings from Five-Year Clinical Study of Traumatic Brain Injury and Oxidation-Reduction Potential at 2014 American Academy of Surgical Trauma Meeting

Date: August 19, 2014 | READ MORE >

Ampio Announces Very Positive Results of the Open Label Portion of the Multiple Intra-articular Injections Study of Ampion™ in Patients with Osteoarthritis of the Knee at Week Six of the Trial

Date: August 18, 2014 | READ MORE >

Luoxis Broadens Global Research Network for RedoxSYS™ ORP (oxidation-reduction potential) diagnostic system; Announces 17 Studies Currently Underway and Additional 30 Studies Set to Begin in 2014

Date: August 11, 2014 | READ MORE >

Ampio announces positive results on the open label portion of the Multiple injection Study of Ampion™ in patients with osteoarthritis of the knee.

Date: August 5, 2014 | READ MORE >

Ampio Pharmaceuticals announces the FDA has issued a written response and accepted the Ampio plan for beginning production of Ampion™ in the new facility.

Date: July 30, 2014 | READ MORE >

Ampio Pharmaceuticals announces the opening of its new headquarters, manufacturing and research facility in Englewood Colorado

Date: July 23, 2014 | READ MORE >

Ampio Initiates Study of Multiple Injections of Ampion™ Into the Knees of Patients with OA of the Knee to Assess its Healing and Cartilage Regeneration Effects

Date: June 30, 2014 | READ MORE >

Ampio Pharmaceuticals, in Response to Positive Feedback, Closes Enrollment in the OptimEyes Study (OptinaTM) and Will Present the Data to the FDA for Guidance

Date: June 25, 2014 | READ MORE >

Ampio Pharmaceuticals Announces Appointment of Gregory A. Gould as Chief Financial Officer

Date: June 5, 2014 | READ MORE >

Ampio Pharmaceuticals to present at the Jefferies 2014 Global Healthcare Conference on Tuesday, June 3rd at 8:30 AM

Date: May 21, 2014 | READ MORE >

Luoxis Awarded Health Canada Approval for RedoxSYS™ Diagnostic System

Date: April 22, 2014 | READ MORE >

Ampio Pharmaceuticals’ Vyrix Files Registration Statement for Proposed Initial Public Offering

Date: April 21, 2014 | READ MORE >

Ampio Pharmaceuticals’ Vyrix Enters into an Agreement with Paladin Labs for Exclusive Rights to Zertane™ in Canada and Other Territories to Broaden its International Footprint

Date: April 10, 2014 | READ MORE >

Results from the 20 weeks extension of the Ampion™ SPRING study to be presented at the Western Orthopedic Association Conference

Date: April 9, 2014 | READ MORE >

Luoxis Obtains CE Marking for RedoxSYS Diagnostic System

Date: April 2, 2014 | READ MORE >

Ampio Announces Investor call Thursday March 13, 4 PM EST.

Date: March 11, 2014 | READ MORE >

AMPIO PHARMACEUTICALS, INC. CLOSES SALE OF 9,775,000 SHARES OF COMMON STOCK

Date: March 5, 2014 | READ MORE >

AMPIO PHARMACEUTICALS, INC. ANNOUNCES PRICING OF PUBLIC OFFERING OF 8,500,000 SHARES OF COMMON STOCK

Date: February 27, 2014 | READ MORE >

Ampio Pharmaceuticals, Inc. Announces Public Offering of Common Stock

Date: February 24, 2014 | READ MORE >

Ampio Completes Enrollment and Dosing in 2nd Pivotal Clinical Trial for Ampion™ (The STEP Study) for Its FDA Biological License Application (BLA)

Date: February 18, 2014 | READ MORE >

Ampio Announces Positive Preliminary Biochemical Findings from the Synovial Fluid of the Knees Treated in the SPRING Study

Date: February 13, 2014 | READ MORE >

Ampio Pharmaceuticals announces publication of findings for its lead product, Ampion™ in the journal PLOS ONE

Date: February 4, 2014 | READ MORE >

Ampio Pharmaceutical Breaks Ground on Construction of Ampion™ Manufacturing Facility

Date: January 15, 2014 | READ MORE >

Ampio Injects First Patients in 2nd Phase III, Pivotal Clinical Trial for Ampion™(The STEP Study) for Its FDA Biological License Application (BLA)

Date: January 13, 2014 | READ MORE >

Luoxis Awarded ISO 13485:2003 and ISO 9001:2008 Certifications

Date: January 9, 2014 | READ MORE >

Luoxis Establishes Study Collaborations with Two Research Centers in Oxidative Stress

Date: January 6, 2014 | READ MORE >